Global Non-Insulin Therapies for Diabetes Market Research Report 2012-2024

Table of Contents

1 Market Overview

• 1.1 Objectives of Research
  • 1.1.1 Definition
  • 1.1.2 Specifications
• 1.2 Market Segment
  • 1.2.1 by Type
    • 1.2.1.1 Alpha-glucosidase Inhibitors
    • 1.2.1.2 Amylin Agonists
    • 1.2.1.3 Biguanides
    • 1.2.1.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
    • 1.2.1.5 Glinides / Meglitinides
    • 1.2.1.6 GLP-1 Analogs / GLP-1 Agonists
    • 1.2.1.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
    • 1.2.1.8 Sulfonylureas
    • 1.2.1.9 Thiazolidinediones
    • 1.2.1.10 Others
  • 1.2.2 by Application
    • 1.2.2.1 Hospital Pharmacy
    • 1.2.2.2 Retail Pharmacies
    • 1.2.2.3 Online Pharmacy
    • 1.2.2.4 Others
  • 1.2.3 by Regions

2 Industry Chain

• 2.1 Industry Chain Structure
• 2.2 Upstream
• 2.3 Market
  • 2.3.1 SWOT
  • 2.3.2 Dynamics

3 Environmental Analysis

• 3.1 Policy
• 3.2 Economic
• 3.3 Technology
• 3.4 Market Entry

4 Market Segmentation by Type

• 4.1 Market Size
  • 4.1.1 Alpha-glucosidase Inhibitors Market, 2013-2018
  • 4.1.2 Amylin Agonists Market, 2013-2018
  • 4.1.3 Biguanides Market, 2013-2018
  • 4.1.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market, 2013-2018
  • 4.1.5 Glinides / Meglitinides Market, 2013-2018
  • 4.1.6 GLP-1 Analogs / GLP-1 Agonists Market, 2013-2018
  • 4.1.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Market, 2013-2018
  • 4.1.8 Sulfonylureas Market, 2013-2018
  • 4.1.9 Thiazolidinediones Market, 2013-2018
  • 4.1.10 Others Market, 2013-2018
• 4.2 Market Forecast
  • 4.2.1 Alpha-glucosidase Inhibitors Market Forecast, 2019-2024
  • 4.2.2 Amylin Agonists Market Forecast, 2019-2024
  • 4.2.3 Biguanides Market Forecast, 2019-2024
  • 4.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors Market Forecast, 2019-2024
  • 4.2.5 Glinides / Meglitinides Market Forecast, 2019-2024
  • 4.2.6 GLP-1 Analogs / GLP-1 Agonists Market Forecast, 2019-2024
  • 4.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Market Forecast, 2019-2024
  • 4.2.8 Sulfonylureas Market Forecast, 2019-2024
  • 4.2.9 Thiazolidinediones Market Forecast, 2019-2024
  • 4.2.10 Others Market Forecast, 2019-2024

5 Market Segmentation by Application

• 5.1 Market Size
  • 5.1.1 Hospital Pharmacy Market, 2013-2018
  • 5.1.2 Retail Pharmacies Market, 2013-2018
  • 5.1.3 Online Pharmacy Market, 2013-2018
  • 5.1.4 Others Market, 2013-2018
• 5.2 Market Forecast
  • 5.2.1 Hospital Pharmacy Market Forecast, 2019-2024
  • 5.2.2 Retail Pharmacies Market Forecast, 2019-2024
  • 5.2.3 Online Pharmacy Market Forecast, 2019-2024
  • 5.2.4 Others Market Forecast, 2019-2024

6 Market Segmentation by Region

• 6.1 Market Size
  • 6.1.1 Asia-Pacific
    • 6.1.1.1 Asia-Pacific Market, 2012-2018
    • 6.1.1.2 Asia-Pacific Market by Type
    • 6.1.1.3 Asia-Pacific Market by Application
  • 6.1.2 North America
    • 6.1.2.1 North America Market, 2012-2018
    • 6.1.2.2 North America Market by Type
    • 6.1.2.3 North America Market by Application
  • 6.1.3 Europe
    • 6.1.3.1 Europe Market, 2012-2018
    • 6.1.3.2 Europe Market by Type
    • 6.1.3.3 Europe Market by Application
  • 6.1.4 South America
    • 6.1.4.1 South America Market, 2012-2018
    • 6.1.4.2 South America Market by Type
    • 6.1.4.3 South America Market by Application
  • 6.1.5 Middle East & Africa
    • 6.1.5.1 Middle East & Africa Market, 2012-2018
    • 6.1.5.2 Middle East & Africa Market by Type
    • 6.1.5.3 Middle East & Africa Market by Application
• 6.2 Market Forecast
  • 6.2.1 Asia-Pacific Market Forecast, 2019-2024
  • 6.2.2 North America Market Forecast, 2019-2024
  • 6.2.3 Europe Market Forecast, 2019-2024
  • 6.2.4 South America Market Forecast, 2019-2024
  • 6.2.5 Middle East & Africa Market Forecast, 2019-2024

7 Market Competitive

• 7.1 Global Market by Vendors
• 7.2 Market Concentration
• 7.3 Price & Factors
• 7.4 Marketing Channel

8 Major Vendors

• 8.1 GSK
• 8.2 Eli Lilly
• 8.3 Sumitomo Dainippon Pharma
• 8.4 Intarcia Therapeutics
• 8.5 Servier
• 8.6 Jiangsu Hansoh Pharmaceutical
• 8.7 Novo Nordisk
• 8.8 Emisphere
• 8.9 Uni-Bio Science Group
• 8.10 Takeda
• 8.11 3SBio
• 8.12 Merck
• 8.13 Dong-A Pharmaceutical
• 8.14 Luye Pharma Group
• 8.15 Eurofarma
• 8.16 Geropharm
• 8.17 Alkem Labs
• 8.18 SatRx
• 8.19 Pfizer
• 8.20 Jiangsu Hengrui Medicine

9 Conclusion